Lv4
620 积分 2021-08-09 加入
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
1天前
已完结
Time-Updated Changes in Estimated GFR and Proteinuria and Major Adverse Cardiac Events: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study
15天前
已完结
Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria
21天前
已完结
Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis
21天前
已完结
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
1个月前
已完结
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis
3个月前
已完结
The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes
3个月前
已完结
Achievement of Guideline-Recommended Targets in Diabetes Care in China
4个月前
已完结
Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 3 trial
4个月前
已完结
皖公网安备34019202002308
